Peer-reviewed veterinary case report
Oral chemotherapy with PPC drugs helps dogs with lymphoma
By K. O’Connell et al.·Published in Veterinary and Comparative Oncology·2022·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Procarbazine, prednisolone and cyclophosphamide (PPC) oral combination chemotherapy protocol for canine lymphoma.
- Species:
- dog
Plain-English summary
A group of dogs with multicentric lymphoma, a type of cancer affecting the lymph nodes, were treated with a new oral chemotherapy combination of procarbazine, prednisolone, and cyclophosphamide. This treatment was given daily and aimed to help dogs that had not responded well to previous chemotherapy. Out of fifty dogs, 70% showed a positive response, with 46% achieving complete remission. Most dogs tolerated the treatment well, with only one needing to stop due to low platelet levels, and a few experiencing mild gastrointestinal issues. Overall, this oral chemotherapy protocol appears to be a promising option for dogs with lymphoma.
People also search for: dog lymphoma treatment · oral chemotherapy for dogs · canine cancer survival rates
Abstract
Orally administered daily chemotherapy offers a novel treatment approach for canine lymphoma in a population of dogs that have failed or not tolerated maximum tolerable dose chemotherapy. A multidrug oral chemotherapy protocol was designed and implemented for the treatment of fifty dogs with multicentric lymphoma with minimal side effects. The protocol consisted of oral procarbazine, prednisolone and cyclophosphamide (PPC) administered daily. Efficacy and toxicity were evaluated by clinical and laboratory evaluation. An overall response rate of 70% was achieved, with 24% and 46% of dogs having a partial and complete response, respectively, to treatment with the PPC protocol. Response to the PPC protocol (complete or partial) and age were the only factors identified as prognostic for time from initiation of the PPC chemotherapy until death. Overall, the protocol was very well tolerated with only one dog requiring protocol discontinuation due to grade 4 thrombocytopenia. Eight dogs recorded gastrointestinal toxicities, seven grade I and one grade II toxicity. These findings demonstrate that the administration of a continuous oral combination chemotherapy can provide comparable survival times in the rescue setting in dogs with multicentric lymphoma with minimal side effects.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/35338560